Q2 EPS Forecast for MiNK Therapeutics Increased by Analyst

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Analysts at HC Wainwright upped their Q2 2026 earnings estimates for shares of MiNK Therapeutics in a research note issued to investors on Monday, May 18th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.60) per share for the quarter, up from their prior estimate of ($0.87). HC Wainwright has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($3.27) per share. HC Wainwright also issued estimates for MiNK Therapeutics’ Q3 2026 earnings at ($0.63) EPS, Q4 2026 earnings at ($0.66) EPS, FY2026 earnings at ($2.46) EPS, FY2027 earnings at ($2.39) EPS, FY2028 earnings at ($3.49) EPS, FY2029 earnings at ($2.07) EPS and FY2030 earnings at $0.05 EPS.

MiNK Therapeutics (NASDAQ:INKT) last announced its earnings results on Friday, May 15th. The company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.20.

A number of other equities analysts have also weighed in on the stock. Wall Street Zen raised shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings lowered shares of MiNK Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, MiNK Therapeutics currently has an average rating of “Hold” and an average price target of $35.00.

MiNK Therapeutics Trading Up 3.1%

Shares of NASDAQ INKT opened at $10.35 on Wednesday. The firm has a market cap of $51.54 million, a PE ratio of -3.64 and a beta of 0.47. MiNK Therapeutics has a 1-year low of $6.65 and a 1-year high of $76.00. The company has a fifty day moving average price of $10.99 and a 200 day moving average price of $11.53.

Hedge Funds Weigh In On MiNK Therapeutics

An institutional investor recently bought a new position in MiNK Therapeutics stock. DRW Securities LLC acquired a new position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned about 0.55% of MiNK Therapeutics at the end of the most recent reporting period. 2.87% of the stock is currently owned by institutional investors.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.